tacrolimus 0.1% + fluticasone 0.005 %
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Dermatitis, Atopic
Conditions
Dermatitis, Atopic
Trial Timeline
Feb 1, 2004 โ Jul 1, 2005
NCT ID
NCT00690105About tacrolimus 0.1% + fluticasone 0.005 %
tacrolimus 0.1% + fluticasone 0.005 % is a approved stage product being developed by Astellas Pharma for Dermatitis, Atopic. The current trial status is completed. This product is registered under clinical trial identifier NCT00690105. Target conditions include Dermatitis, Atopic.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00690105 | Approved | Completed |
Competing Products
20 competing products in Dermatitis, Atopic